Sell Alert: 10 Stocks Analysts Downgraded on Friday

8. Cognizant Technology Solutions (NASDAQ:CTSH)

Average Upside Potential: 9%

Number of Hedge Fund Holders: 48

Deutsche Bank downgraded Cognizant to Hold from Buy on November 13 and lowered its price target to $66 from $75. Deutsche Bank analyst Nate Svensson said the growth thesis behind the firm’s earlier Buy rating has not played out. He has less confidence that organic revenue growth will improve soon, expecting it to sit near 2% year over year at the end of 2026 with little identifiable catalyst for 2027.

Cognizant provides information technology, consulting and business process outsourcing services, from application work and cloud migration to AI and core modernization. In the third quarter of 2026, revenue rose 4.6%, financial services revenue grew 12%, and the company revised its 2026 constant currency revenue growth guidance.

Svensson still credits the company’s positioning in large deals and its AI execution, but he no longer thinks the stock deserves a valuation in line with Accenture. The shares have rallied about 67% from the June 30 low alongside the IT services group, even as fundamentals weakened. We covered how Cognizant’s restructuring squares with its message that AI creates jobs in a separate piece.

7. Lowe’s (NYSE:LOW)

Average Upside Potential: 9%

Number of Hedge Fund Holders: 69

Stifel downgraded Lowe’s to Sell from Hold on November 13 and trimmed its price target to $190 from $195, ahead of the retailer’s third-quarter report. Analyst W. Andrew Carter noted that Lowe’s shares have jumped since October 7 and now require a level of certainty the home centers do not offer. He flagged a weaker second half of 2026, operating margin pressure in fiscal 2027 and 2028, and structural issues including weak do-it-yourself demand, housing uncertainty and tougher competition.

Carter sees Lowe’s as more exposed than Home Depot. Nearly 60% of its specialty trade business depends on new home construction, which has weakened, and he thinks building out that platform would take another large acquisition, probably paid for with equity.

Lowe’s sells home improvement products, from appliances and lumber to paint and flooring. In the second quarter of 2026, comparable sales rose 0.2% and the company lowered its full-year comparable sales outlook to flat, from flat to up 2%. Lowe’s is expected to report on November 18, with analysts looking for earnings of $2.89 per share. A separate article covers Lowe’s dividend sustainability and the test facing its returns.

6. Alexandria Real Estate Equities (NYSE:ARE)

Average Upside Potential: 12%

Number of Hedge Fund Holders: 32

BofA Securities downgraded Alexandria Real Estate Equities to Underperform from Neutral on November 13 and cut its price target to $45 from $55. BofA’s Farrell Granath lowered estimates and expects earnings to keep declining through at least 2027. Better leasing is unlikely to fully offset near-term vacancy and tenant wind-downs, and falling capitalized interest and ongoing capital needs add to the pressure.

Alexandria, based in Pasadena, California, leases space to life science, agtech and technology tenants. Alan D. Gold, Gary A. Kreitzer, Joel S. Marcus and Jerry M. Sudarsky founded the company in October 1994. Its results for the third quarter of 2026 showed the strain: a net loss of $3.74 per diluted share, while funds from operations per share, as adjusted, came in at $1.54. Over the first nine months of 2026, the net loss was $2.06 per share and adjusted funds from operations came to $5.00 per share.

We examined the same tension in Alexandria’s profit rebound and the cash flow catch behind it; BofA’s call adds a view of where earnings are heading through at least 2027.

5. National Health Investors (NYSE:NHI)

Average Upside Potential: 18%

Number of Hedge Fund Holders: 20

BofA Securities downgraded National Health Investors to Underperform from Buy on November 13 and cut its price target to $67 from $86. The firm pointed to weaker-than-expected execution in the senior housing operating portfolio, known as SHOP, and a cut to fiscal 2026 guidance. BofA Securities’ earlier Buy rating assumed faster, more accretive redeployment of the proceeds from the NHC portfolio sale and stronger operating progress.

Recent SHOP assets have underperformed, BofA said: capital needs exceeded underwriting, deployment lagged and yields compressed. The firm now expects the ramp to meaningful SHOP accretion to take longer, and it lowered its fiscal 2027 normalized FFO per share estimate to $4.63 from $5.02, which is 5.6% below the Street.

National Health Investors provides sale-leaseback, joint-venture, mortgage and mezzanine financing for senior housing and medical investments. It reports in two segments, Real Estate Investments and SHOP. In the third quarter of 2026, reported on November 9, Chief Executive Officer Eric Mendelsohn said the strengthened team had developed a focused plan to address underperformance. The company invested more than $395 million year to date, and it booked a large gain on dispositions, mainly from the NHC portfolio sale.